APONTIS PHARMA AG

APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast

APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications

APONTIS PHARMA expects profitable growth again in 2024

APONTIS PHARMA successfully completes performance and efficiency improvement program

APONTIS PHARMA presents details of the restructuring and efficiency program – Nine-month figures for 2023 and new sales and earnings forecast for 2023 published

APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program

APONTIS PHARMA confirms preliminary figures – H1 2023 sales and earnings decline

APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024

APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 – Preparation of program to increase operating performance and efficiency launched

APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026

APONTIS PHARMA: CEO Karlheinz Gast resigns for personal reasons – Bruno Wohlschlegel takes over as successor

APONTIS PHARMA AG: CEO Karlheinz Gast resigns from office for personal reasons

APONTIS PHARMA launches Single Pill Finder and distribution of Single Pill Rosazimib – First of three launches in 2023

APONTIS PHARMA in Q1 2023 records decline in sales and earnings as expected – 2023 as a transition year in focusing on Single Pills

APONTIS PHARMA: Keeping up high pace in expansion of Single Pill portfolio – New development partnership with Zentiva Group for another Single Pill with EU-wide intellectual property rights

APONTIS PHARMA AG: Silke Reineke, buy

APONTIS PHARMA AG: Thomas Milz, buy

APONTIS PHARMA AG adjusts forecast for fiscal year 2023

APONTIS PHARMA with first in-licensing of a Single Pill with two active ingredients for the primary prophylaxis of cardiovascular events – market launch already planned for early 2024

APONTIS PHARMA: New development partnership with Midas Pharma – Expansion of Single Pill portfolio with EU-wide property rights opens up additional revenue potential

APONTIS PHARMA with successful financial year 2022: Revenue and EBITDA forecast slightly exceeded according to preliminary calculations

APONTIS PHARMA accelerates expansion of Single Pill portfolio with second of three in-licensing deals planned for 2023

APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensing a new Single Pill

APONTIS PHARMA: Number of announced market launches increases to ten Single Pills – Portfolio grows by two in-licensing deals

APONTIS PHARMA confirms 2022 forecast after successful nine-month period – Strong Single Pill pipeline to achieve medium-term targets

APONTIS PHARMA announces cooperation to launch new Single Pill in Germany

APONTIS PHARMA: SECURE study and START study add-on analysis confirm superior efficacy of Single Pill

APONTIS PHARMA expands profitable positioning in first half of 2022 – full-year forecast confirmed

APONTIS PHARMA and Midas Pharma agree on further development partnership for the market launch of a single pill with pan-European intellectual property rights

APONTIS PHARMA rolls out new Single Pill for secondary prophylaxis